Vascular Medicine
Pulmonary embolism
PE diagnosis, treatment, and risk stratification
Emerging pathwayAlso known as: PE, pulmonary thromboembolism, VTE
2,535
Clinical questions
112
Evidence-backed
72
Claims analyzed
Vascular Medicine
PE diagnosis, treatment, and risk stratification
Synthesized from 112 evidence-backed clinical questions linked to this topic — 7 supporting the intervention, 17 against the intervention, 4 still contested.
Does aspirin vs placebo improve outcomes in Pre-Eclampsia?
Low Certainty+ Favors benefitaspirin vs placebo
34 studies (27,331,874 patients) provide low-certainty evidence for benefit of aspirin for the outcome in Pre-Eclampsia.
Does thrombolytics vs placebo improve outcomes in Pulmonary Embolism?
Low Certainty− Favors harmthrombolytics vs placebo
10 studies (1,026,848 patients) provide low-certainty evidence against benefit of thrombolytics for the outcome in Pulmonary Embolism.
Does edoxaban vs placebo improve outcomes in Venous Thromboembolism?
Low Certainty− Favors harmedoxaban vs placebo
7 studies (139,660 patients) provide low-certainty evidence against benefit of edoxaban for the outcome in Venous Thromboembolism.
Does low molecular weight heparin vs placebo improve outcomes in Venous Thromboembolism?
Low Certainty+ Favors benefitlow molecular weight heparin vs placebo
3 studies (68,092 patients) provide low-certainty evidence for benefit of low molecular weight heparin for the outcome in Venous Thromboembolism.
Does thrombolytic agents vs placebo improve outcomes in Acute pulmonary embolism?
Low Certainty+ Favors benefitthrombolytic agents vs placebo · Myocardial Infarction Hospitalization
22 studies (58,789 patients) provide low-certainty evidence for benefit of thrombolytic agents for Myocardial Infarction Hospitalization in Acute pulmonary embolism.
Does thrombolysis vs anticoagulation improve outcomes in submassive pulmonary embolism?
Low Certainty+ Favors benefitthrombolysis vs anticoagulation
6 studies (58,734 patients) provide low-certainty evidence for benefit of thrombolysis for the outcome in submassive pulmonary embolism.
Does heparin, porcine vs placebo improve outcomes in Pulmonary Embolism?
Insufficient~ Mixed resultsheparin, porcine vs placebo
5 studies (1,410 patients) provide insufficient evidence with mixed findings regarding heparin, porcine for the outcome in Pulmonary Embolism.
Does apixaban vs placebo improve outcomes in Thromboembolism?
Insufficient~ Mixed resultsapixaban vs placebo
2 studies (0 patients) provide insufficient evidence with mixed findings regarding apixaban for the outcome in Thromboembolism.
Emerging evidence with 72 primary claims
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Does thrombolytic agents vs placebo improve outcomes in Acute pulmonary embolism?
Low Certainty+ Favors benefitthrombolytic agents vs placebo · Myocardial Infarction Hospitalization
Does anticoagulation vs placebo improve All-Cause Mortality in Acute pulmonary embolism?
Low Certainty− Favors harmanticoagulation vs placebo · All-Cause Mortality
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
Pulmonary embolism (also known as PE, pulmonary thromboembolism, VTE). PE diagnosis, treatment, and risk stratification
Synapse tracks 6 specific clinical questions in Pulmonary embolism, each synthesized independently from its own trial evidence. They include: "Does thrombolytic agents vs placebo improve outcomes in Acute pulmonary embolism?"; "Does anticoagulation vs placebo improve All-Cause Mortality in Acute pulmonary embolism?"; "Does anticoagulation vs placebo improve outcomes in Pulmonary Embolism?"; "Does anticoagulation vs placebo improve Hospital Length of Stay in Pulmonary Embolism?"; "Does thrombolytics vs anticoagulants improve Major Bleeding in Pulmonary Embolism?".
As of 2026-08-14, the scientific consensus on Pulmonary embolism is emerging. Emerging evidence with 72 primary claims Based on 72 analyzed claims across Synapse's enriched corpus, the evidence shows.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/pulmonary-embolism.
Deterministic synthesis from Synapse's enriched corpus — 127 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every Pulmonary embolism paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search Pulmonary embolism papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers